RT Journal Article
SR Electronic
T1 Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults with hybrid immunity against COVID-19: a multicenter, partially randomized, platform trial in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.14.24313671
DO 10.1101/2024.09.14.24313671
A1 Jia, Si-Yue
A1 Liu, Yuan-Bao
A1 He, Qian
A1 Pan, Hong-Xing
A1 Liang, Zheng-Lun
A1 Zhou, Juan
A1 Pan, Ying-Zi
A1 Liu, Sheng
A1 Wu, Jing-Jing
A1 Yang, Kun
A1 Zhang, Xuan-Xuan
A1 Zhao, Yang
A1 Li, Si-Min
A1 Zhang, Lei
A1 Chen, Li
A1 Yao, Ai-Hua
A1 Lu, Meng-Yi
A1 Mao, Qun-Ying
A1 Zhu, Feng-Cai
A1 Li, Jing-Xin
YR 2024
UL http://medrxiv.org/content/early/2024/09/15/2024.09.14.24313671.abstract
AB Background The primary objective of this research was to assess if a booster dose with COVID-19 vaccines containing ancestral strain could still provide significant protection against symptomatic SARS-CoV-2 infection in a predominantly hybrid-immune population during the period of omicron variant dominance.Methods We did a multicenter, partially randomized, platform trial to evaluate the effectiveness of a booster dose of an aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) in adults, after the national-wide omicron circulating at the end of year 2022 in China. Participants who were willing to receive a COVID-19 booster dose were randomly assigned to receive one of the booster doses. While, those participants who refused to take a booster dose but consented to participate COVID-19 surveillance were included in a control group. Both participants receiving a booster dose or not were monitored for symptomatic COVID-19 during a six-month surveillance period.Results Between May 23, 2023, and August 28, 2023, 4089 eligible participants were equally randomized to receive a booster dose of aerosolized Ad5-nCoV through oral inhalation at 0.1mL (IH Ad5-nCoV, n=2039) or intramuscular injection of Ad5-nCoV at 0.5 mL (IM Ad5-nCoV, n=2050). While, 2008 participants were enrolled in the blank-control group. A total of 79 COVID-19 cases were confirmed, with 22 (0.006%) in the IH Ad5-nCoV group, 23 (0.007%) in the IM Ad5-nCoV group, and 34 (0.01%) in the control group. Adjusted effectiveness of IH Ad5-nCoV and IM Ad5-nCoV from 14 days after the vaccination were 51.6% (95% CI 9.0 to 74.3) and 38.1% (95% CI - 9.6 to 65.1), respectively.Interpretation Significant protection against symptomatic COVID-19 caused by the Omicron variant, during the ongoing pandemic of evolving COVID-19 variants, was found to be provided by boosting with the ancestral strain-containing vaccine IH Ad5-nCoV, but not by boosting with IM Ad5-nCoV.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05855408Funding StatementThis study was funded by National Key Research and Development Program of China (grant number 2023YFC2307601), National Natural Science Foundation of China (grant numbers 82341031, 82173584, and 82222062), Major Research Plan of the National Natural Science Foundation of China (grant number 92269205), Jiangsu Provincial Science Fund for Distinguished Young Scholars (grant number BK20220064), Jiangsu Provincial Key Project of Science and Technology Plan (grant numbers BE2021738 and BE2023601), and Fund of State Key Laboratory of Drug Regulatory Science (grant number 2023SKLDRS0114)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Jiangsu Provincial Center for Disease Control and Prevention gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors